

ASX ANNOUNCEMENT: APPENDIX 4C

31 July 2015

The Manager
Company Announcements Office
ASX Limited
20 Bridge St
SYDNEY NSW 2000

Dear Sir

APPENDIX 4C

Invion Limited (ASX:IVX) is pleased to lodge its Appendix 4C for the quarter ending 30 June 2015.

The Company held cash reserves of \$2.285 million at the end of June, consistent with budget forecasts. Cash outflows relating to operating expenses were \$4.479 million, with spend on direct R&D activities at approximately \$3.168 million.

During the quarter the Company announced that it had presented INV102 (oral nadolol) data to the American Thoracic Society (ATS) meeting in Denver, Colorado. The Company detailed how its phase II study of INV102 as an aid to smoking cessation had confirmed Invion's hypothesis that patients with chronic cough due to cigarette smoking could be studied as a single population based on biomarker results, whether or not they had evidence of airflow obstruction. The presentation also noted earlier results from this study which had indicated that key signs of respiratory inflammation could be reduced in as little as four weeks of treatment versus placebo.

Also during the quarter, the Company announced that it had completed dosing in INVSC001: "Efficacy and safety of beta-adrenoceptor inverse agonist, nadolol, in smoking cessation of patients with pre-existing COPD", noting that headline study data was expected in Q3 2015.

Subsequent to the end of the quarter, the Company announced that it had entered into a joint development and licensing agreement with Hovione Scientia Limited, for the development of a dry powder formulation of INV104 (zafirlukast) to be delivered by Hovione's inhaler as a potential therapy for asthma.

The cash position of the Company is under constant review by the Board, and the Board is considering its options to ensure that cash resources are in place to see the Company through its forthcoming clinical development and business milestones.

An Appendix 4C accompanies this announcement.

For and on behalf of the Board of Invion Limited

MELANIE FARRIS
Company Secretary

Appendix 4C

Quarterly report
for entities admitted
on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

INVION LIMITED

ABN

76 094 730 417

Quarter ended ("current quarter")

30-June-2015

Consolidated statement of cash flows

Cash flows related to operating activities			Current quarter	Year to date
			\$A'000	(12 months) \$A'000
1.1	Receipts from customers		203	216
	Payments for	(a) staff costs	(435)	(1,846)
		(b) patent costs	(75)	(333)
1.2		(c) research and development	(3,093)	(7,026)
		(d) leased assets	(3)	(11)
		(e) other working capital	(873)	(2,306)
1.3	Dividends received		-	-
1.4	Interest and other items of a similar nature received		3	34
1.5	Interest and other costs of finance paid		(78)	(223)
1.6	Income taxes paid		-	-
1.7	Other	(a) Research & Development tax refund	-	1,176
		(b) Other	-	-
Net operating cash flows			(4,351)	(10,319)

		Current quarter	Year to date (12 months)
		\$A'000	\$A'000
1.8	Net operating cash flows (carried forward)	(4,351)	(10,319)
Cash flows related to investing activities			
1.9	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	(238)
	(d) physical current assets	-	-
	(e) other non-current assets	-	(8)
1.10	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other	-	-
Net investing cash flows		-	(246)
1.14	Total operating and investing cash flows	(4,351)	(10,565)
Cash flows related to financing activities			
1.15	Proceeds from issues of shares	3,991	6,287
1.16	Proceeds from shares not yet issued	-	(400)
1.17	Proceeds from borrowings	3,492	4,692
1.18	Repayment of borrowings	(1,110)	(1,110)
1.19	Dividends paid	-	-
1.2	Other Creditors (costs of fund raising)	(450)	(623)
Net financing cash flows		5,923	8,846
Net increase (decrease) in cash held		1,572	(1,719)
1.21	Cash at beginning of quarter/year to date	659	3,954
1.22	Exchange rate adjustments to item 1.20	54	50
1.23	Cash at end of quarter/year to date	2,285	2,285

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

	Current quarter \$A'000
1.24 Aggregate amount of payments to the parties included in item 1.2 (a)	160
1.25 Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Payments to directors includes directors fees, and salaries and other payments, including termination payments, to executive directors.

Separate to the amounts noted at 1.24 above, for the quarter, approximately \$29,600 in fees were paid or were payable to McCullough Robertson Lawyers. Mr Brett Heading is a Partner at McCullough Robertson Lawyers.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cashflows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities	1,042,008	1,042,008
3.2 Credit standby arrangements	-	-
3.3 Convertible loan facility	-	-

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.

	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	2,285	659
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)	2,285	659

Acquisitions and disposals of business entities

	Acquisitions	Disposals
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

This statement has been prepared under accounting policies which comply with accounting standards as
1 defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

2 This statement does give a true and fair view of the matters disclosed.

Sign here: Original signed
(Company Secretary)

Date: 31-July-2015

Print name: Melanie Farris